Cronos Australia Limited operates as a medicinal cannabis company in Australia and Asia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.17|
|52 Week High||AU$0.076|
|52 Week Low||AU$0.20|
|1 Month Change||12.90%|
|3 Month Change||45.83%|
|1 Year Change||101.15%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-48.53%|
Recent News & Updates
|CAU||AU Healthcare||AU Market|
Return vs Industry: CAU exceeded the Australian Healthcare industry which returned 14.2% over the past year.
Return vs Market: CAU exceeded the Australian Market which returned 21.3% over the past year.
Stable Share Price: CAU is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: CAU's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Cronos Australia Limited operates as a medicinal cannabis company in Australia and Asia. It operates through three segments: Medical, Clinics, and Consumer. The company distributes PEACE NATURALS brand medicinal cannabis products; develops and sells medicinal cannabis products under the Adaya brand; and operates medicinal cannabis clinics.
Cronos Australia Fundamentals Summary
|CAU fundamental statistics|
Is CAU overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CAU income statement (TTM)|
|Cost of Revenue||AU$819.91k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.031|
|Net Profit Margin||-239.20%|
How did CAU perform over the long term?See historical performance and comparison
Is Cronos Australia undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CAU's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CAU's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CAU is unprofitable, so we can't compare its PE Ratio to the Australian Healthcare industry average.
PE vs Market: CAU is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CAU's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CAU is overvalued based on its PB Ratio (2.4x) compared to the AU Healthcare industry average (2.1x).
How is Cronos Australia forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cronos Australia has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Cronos Australia performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CAU is currently unprofitable.
Growing Profit Margin: CAU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CAU is unprofitable, and losses have increased over the past 5 years at a rate of 38.9% per year.
Accelerating Growth: Unable to compare CAU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CAU is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (61.3%).
Return on Equity
High ROE: CAU has a negative Return on Equity (-45.6%), as it is currently unprofitable.
How is Cronos Australia's financial position?
Financial Position Analysis
Short Term Liabilities: CAU's short term assets (A$11.8M) exceed its short term liabilities (A$3.2M).
Long Term Liabilities: CAU's short term assets (A$11.8M) exceed its long term liabilities (A$253.7K).
Debt to Equity History and Analysis
Debt Level: CAU's debt to equity ratio (21.8%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if CAU's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CAU has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CAU has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 45.3% each year.
What is Cronos Australia current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CAU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CAU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CAU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CAU's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CAU's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Rodney Damon Cocks, CSM, is an Executive Director and Chief Executive Officer at Cronos Australia Limited since September 27, 2018. Mr. Cocks is a Director of NewSouthern Capital, a private equity firm...
CEO Compensation Analysis
Compensation vs Market: Rodney's total compensation ($USD315.25K) is about average for companies of similar size in the Australian market ($USD302.38K).
Compensation vs Earnings: Rodney's compensation has increased whilst the company is unprofitable.
Experienced Board: CAU's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Cronos Australia Limited's employee growth, exchange listings and data sources
- Name: Cronos Australia Limited
- Ticker: CAU
- Exchange: ASX
- Founded: 2018
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: AU$22.531m
- Shares outstanding: 128.75m
- Website: https://www.cronosaustralia.com
- Cronos Australia Limited
- 299 Toorak Road
- Suite 8
- South Yarra
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/25 16:59|
|End of Day Share Price||2021/10/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.